<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: <z:hpo ids='HP_0001723'>Restrictive cardiomyopathy</z:hpo> due to AL <z:hpo ids='HP_0011034'>amyloidosis</z:hpo> has not been reported as the cause of <z:hpo ids='HP_0001699'>sudden death</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The risk of <z:hpo ids='HP_0001699'>sudden death</z:hpo> in AL <z:hpo ids='HP_0011034'>amyloidosis</z:hpo> may be further increased by potentially cardiotoxic medication, as in the following case.Case report: In a 69-year-old female, AL <z:hpo ids='HP_0011034'>amyloidosis</z:hpo> from <z:e sem="disease" ids="C0238239" disease_type="Disease or Syndrome" abbrv="">light-chain deposition disease</z:e> manifested as gastrointestinal pseudo-obstruction, <z:hpo ids='HP_0001723'>restrictive cardiomyopathy</z:hpo>, and secondary <z:hpo ids='HP_0003198'>myopathy</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>AL <z:hpo ids='HP_0011034'>amyloidosis</z:hpo> was histologically confirmed by endomyocardial biopsy and muscle biopsy </plain></SENT>
<SENT sid="3" pm="."><plain>One month after initiation of steroids and lenalidomide the patient suddenly died during sleep </plain></SENT>
<SENT sid="4" pm="."><plain>It is speculated that <z:hpo ids='HP_0001699'>sudden death</z:hpo> was due to <z:hpo ids='HP_0001723'>restrictive cardiomyopathy</z:hpo>, cardiotoxicity of lenalidomide, <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo>, sudden unexplained <z:hpo ids='HP_0011420'>death</z:hpo> in <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> syndrome or <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>The possible causes of <z:hpo ids='HP_0001699'>sudden death</z:hpo> are discussed </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: This case shows that AL <z:hpo ids='HP_0011034'>amyloidosis</z:hpo> from <z:e sem="disease" ids="C0238239" disease_type="Disease or Syndrome" abbrv="">light-chain deposition disease</z:e> may predominantly affect the intestines, myocardium and the skeletal muscle and that lenalidomide may have a beneficial effect on the <z:hpo ids='HP_0011034'>amyloidosis</z:hpo> but should be given with caution for its potential arrhythmogenic and thrombogenic side-effects </plain></SENT>
</text></document>